Renal & Urology News’ Post

ℹ️ The insights from this systematic review https://lnkd.in/g8QC4CtW underscore the importance of considering thromboprophylaxis in prostate cancer patients on PARP inhibitors. Let's prioritize preventative measures 💪🩺 #Thromboprophylaxis #CancerCare

Thrilled to share with you all the publication of our research paper, titled: "Mathematical model of MMC chemotherapy for non-invasive bladder cancer treatment", in Frontiers in Oncology. #mathonco https://lnkd.in/d44zsmau

In Actinium-225 PSMA therapy, a radiolabeled molecule targets PSMA, delivering the radioactive Actinium-225 directly to prostate cancer cells. This therapy is particularly effective in treating metastatic prostate cancer, where cancer has spread to other parts of the body and is resistant to other forms of treatment. #ac225 #actinium225psma #prostatecancer #cancertreatmentistanbul #istanbul https://lnkd.in/dp4Rjvib

Want to learn more about the relevance of detecting PSMA positivity in advanced prostate cancer patients from a simple blood test? Check out this great interview in Targeted Oncology with our collaborator Dr. Jacob Berchuck. https://bit.ly/4e7gBvE #ProstateCancer #Epigenomics #PrecisionMedicine #DrugDevelopment

Interesting study in Clinical Cancer Research: A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer https://lnkd.in/eHJr-3Y9 Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: Patients with mCRPC refractory to androgen receptor pathway inhibitor therapy and taxane-based chemotherapy received target acapatamab doses ranging from 0.003 mg–0.9 mg in dose exploration (7 dose levels) and 0.3 mg (recommended phase 2 dose) in dose expansion intravenously Q2W. Safety (primary objective), pharmacokinetics, and antitumor activity (secondary objectives) were assessed. Results: In all, 133 patients (dose exploration, n=77; dose expansion, n=56) received acapatamab. Cytokine release syndrome (CRS) was the most common treatment-emergent adverse event seen in 97.4% and 98.2% of patients in dose exploration and dose expansion respectively; grade ≥ 3 was seen in 23.4% and 16.1%, respectively. Most CRS events were seen in treatment cycle 1; incidence and severity decreased at/beyond cycle 2. In dose expansion, confirmed prostate-specific antigen responses (PSA50) were seen in 30.4% of patients and radiographic partial responses in 7.4% (RECIST 1.1). Median PSA progression-free survival (PFS) was 3.3 months (95% CI, 3.0–4.9), radiographic PFS per PCWG3 was 3.7 months (95% CI, 2.0–5.4). Acapatamab induced T-cell activation and increased cytokine production several-fold within 24h of initiation. Treatment-emergent antidrug antibodies were detected in 55% and impacted serum exposures in 36% of patients in dose expansion. Conclusions: Acapatamab was safe and tolerated and had a manageable CRS profile. Preliminary signs of efficacy with limited durable antitumor activity were observed. Acapatamab demonstrated pharmacokinetic and pharmacodynamic activity.

Trimodal therapy consisting of radiation plus chemotherapy and transurethral resection is an effective potential alternative to radical cystectomy for high-grade T1 bladder cancer. https://brnw.ch/21wMFMj #blcsm

Great publication from our collaborator Rui Wang and colleagues showing that in colorectal cancer cells LRG1 activates the PI3K-PDK1-RSK-elF4B pathway through the HER3 receptor promoting metastatic growth. Importantly, inhibiting LRG1 improves outcome yet again demonstrating LRG1 as a promising target in cancer. https://lnkd.in/ewHBsRHt

ARV-766: another interesting new drug in development for metastatic castrate resistant prostate cancer (mCRPC) with promising early phase data presented at #ASCO24. ARV-766 is an AR "PROTAC," a molecule that enhances degradation of the androgen receptor (AR) inside of prostate cancer cells. 20-25% of patients with mCRPC have tumor mutations in the AR ligand binding domain (LBD). In a small cohort of heavily pretreated mCRPC patients whose tumors had mutations in the AR LBD, ARV-766 led to a 50% decrease in PSA levels in 43% of patients. Impressive preliminary data for this patient population.

The inter-tumoral complexity of metastatic castration-resistant prostate cancer poses a treatment challenge that may be tackled by examining clonal evolution. #NYGU https://lnkd.in/e_c6ZH-g

Learn about some new pancreatic research coming out of MUSC Hollings Cancer Center! https://lnkd.in/gK2DMNgB #PancreaticCancer #SouthCarolina #Cancer #CancerResearch